# Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct05624996/  
OnCo record `nct05624996` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of carboplatin, cisplatin, durvalumab, etoposide and other drugs in lung cancer, run by NRG Oncology, now recruiting.

## Summary

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT05624996 by NRG Oncology, with a registry enrolment figure of 474 participants, started 2023-07-12 and due to reach its primary completion in 2031-10-15. Interventions recorded: Carboplatin; Cisplatin; Computed Tomography; Durvalumab; Etoposide; Image Guided Radiation Therapy; Nab-paclitaxel; Osimertinib; Paclitaxel; Pemetrexed; Positron Emission Tomography; Questionnaire Administration; Stereotactic Body Radiation Therapy. Conditions listed: Locally Advanced Lung Non-Small Cell Carcinoma; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8. Primary outcome: Overall survival (OS); Progression-free survival (PFS). Lung eligibility wording from the registry: "* Pathologically (histologically or cytologically) proven diagnosis of non-operable stage IIB or III, node positive (American Joint Committee on Cancer \[AJCC\] eighth edition) non-small cell lung cancer (NSCLC) with known PD-L1 status prior to registration". Sites: Canada, United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05624996
- Phase: 3
- Setting: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer
- Sponsor: NRG Oncology
- Enrolled: 474

## Sources

- ClinicalTrials.gov NCT05624996: https://clinicaltrials.gov/study/NCT05624996

## Connected records

- cancers: [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Etoposide](https://onco.cc/drugs/etoposide/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05624996.json